Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

VEGF Trap-Eye May Be Focused on Wrong Target

February 26, 2010

Analysis of:VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema | www.pipelinereview.com

VEGF Trap-Eye is a anti-VEGF medication that may be used to treat macular degeneration, and in this article, diabetic macular edema. While the results are favorable in this phase II news release, the standard of care may no longer be laser treatment by the time this study is actually completed. Advances in sustained release drug delivery may already dominate the market by the end of this study taking away any significance to the efficacy of this pending study.

Alimera's Iluvien Nears FDA Approval for Sustained Release Retina Treatment

January 20, 2010

Analysis of:Alimera Announces Positive Results from the Two Phase 3 FAME Trials of Iluvien in Patients with Diabetic Macular Edema | www.alimerasciences.com

Alimera's Iluvien nears completion of Phase 3 clinical trials and seems likely to submit NDA this second quarter.Iluvien will be the second product to enter the expanding market of sustained release intraocular drug delivery. It is similar to Ozurdex (Allergan) in that it will release steroids into the eye for months. The clinical application of Iluvien; however, includes patients with diabetic retinopathy and may challenge laser photocoagulation.

Ozurdex (Allergan) Uses Billing Structure That May Prevent Acceptance

November 9, 2009

Analysis of:Dexamethasone implant a first for macular edema after retinal vein occlusion | ophthalmologytimes.modernmedicine.com

Ozurdex (Allergan) is now on the market and available for ophthalmologists to treat patients with retinal vascular occlusions (RVO).While the technology and treatment may be sound, there may be significant hurdles to overcome from a billing standpoint.Ozurdex may follow the same fate as Lucentis (Genetech). It must compete with a much cheaper drug which has comparable efficacy.

Ozurdex Opens Doors for All Retinal Treatment, Not Just Retinal Vein Occlusions

June 24, 2009

Analysis of:FDA Approval of Ozurdex Introduces a New Generation of Drug Delivery Therapy | www.drugs.com

Ozurdex is the first biodegradable drug delivery system for the eye. Approved for retinal vein occlusions, the off-label use will ensure wider use than the FDA approval. Ozudex may supplant intravitreal injections and the novel technology may be useful in treatment of macular degeneration and diabetics.

New Developments in Ocular Inflammation

June 24, 2009

Analysis of:steroids in eye surgery | www.siriontherapeutics.com

Recent developments in pharmaceuticals and technology now give us more choices for treating intraocular inflammation. Newer developments in eyedrops now give us different "strengths" of steroid eyedrops. New drug delivery systems will be giving us sustained release of steroids.

Novagali Phase II Results are Cyclokat (R) for Dry Eye Promising

April 17, 2009

Analysis of:Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye | www.pipelinereview.com

Promising results from Novagali's phase II study of their novel product Cyclokat is very promising for the moderate to severe dry eye patient. Once a day dosing is a real plus.

Othera's Eye Drop to Cure ARMD Seems Promising But Too Early to Tell

April 16, 2009

Analysis of:Eye drop treatment for dry AMD shows promise in Phase 2 trial | www.othera.com

An eye drop that stabilizes the most common form of AMD is encouraging. The ability for an eye drop to be effective is curious. Historically it has been difficult to get any medication effectively delivered to the retina via topical medications. The development of geographic atrophy is very, very slow and it is surprising that a positive trend can be noted in such a short time.

Wal-Mart's Plans to Enter EMR Market

March 20, 2009

Analysis of:Wal-Mart Plans to Market System for Digital Health Records - NYTimes.com | www.nytimes.com

Walmart's plan to introduce EMR to their demographic is bold, but does not address the key problems of cost, in dollars and man hours, and poor appreciation of computers by the physican community. EMR has a bad connotation amongst physicians, it is a "black box" that is expensive to implement. Most small offices work rather efficiently. Large offices are so inefficient that present EMR systems do offer an advantage.

Page : 11 to 8 of 8

Subscribe to Updates

By RSS